ZEN-3694 is under clinical development by Zenith Epigenetics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ZEN-3694’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 22 Sep 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ZEN-3694 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ZEN-3694 overview

ZEN-3694 is under development for the treatment of metastatic castration-resistant prostate cancer, acute myelocytic leukemia, solid tumors such as epithelial ovarian cancer, lung cancer, colon cancer, lymphoma, pancreatic cancer, melanoma, NUT midline carcinoma, triple negative breast cancer, ovarian cancer, fallopian tube cancer and primary peritoneal carcinoma. The drug candidate is administered through oral route. The drug candidate acts by targeting BRD2, BRD3, BRD4 and BRDT.

Zenith Epigenetics overview

Zenith Epigenetics, a subsidiary of Zenith Capital Corp, is a clinical-stage biotechnology company that focuses on the discovery and development of small molecules for the inhibition of BET bromodomains. The company’s lead product ZEN-3694 is a BET inhibitor intended for the treatment of solid tumors, including metastatic prostate cancer. Its platform integrates structural biology, medicinal chemistry and modeling with biochemical and cell-based assays. The company has a presence in Canada and the US. Zenith Epigenetics is headquartered in Calgary, Alberta, Canada.

Quick View ZEN-3694 LOA Data

Report Segments
  • Innovator
Drug Name
  • ZEN-3694
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.